TG Therapeutics, Inc. (TGTX)
USD 34.75
(-6.96%)
USD 34.75
(-6.96%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 20.63 Million USD | 110.7% |
| 2022 | -192.83 Million USD | 44.07% |
| 2021 | -344.77 Million USD | -26.02% |
| 2020 | -273.59 Million USD | -61.84% |
| 2019 | -169.05 Million USD | 3.06% |
| 2018 | -174.4 Million USD | -46.91% |
| 2017 | -118.71 Million USD | -50.33% |
| 2016 | -78.96 Million USD | -24.99% |
| 2015 | -63.18 Million USD | -13.39% |
| 2014 | -55.72 Million USD | -142.62% |
| 2013 | -22.96 Million USD | 14.61% |
| 2012 | -26.89 Million USD | -2949.42% |
| 2011 | -881.97 Thousand USD | 56.27% |
| 2010 | -2.01 Million USD | -13.84% |
| 2009 | -1.77 Million USD | 59.85% |
| 2008 | -4.41 Million USD | 63.66% |
| 2007 | -12.14 Million USD | -21.44% |
| 2006 | -10 Million USD | 48.34% |
| 2005 | -19.35 Million USD | -215.12% |
| 2004 | -6.14 Million USD | -29.1% |
| 2003 | -4.75 Million USD | -206.41% |
| 2002 | -1.55 Million USD | 50.02% |
| 2001 | -3.1 Million USD | 1.74% |
| 2000 | -3.16 Million USD | -17.13% |
| 1999 | -2.7 Million USD | 0.0% |
| 1998 | -2.7 Million USD | 49.06% |
| 1997 | -5.3 Million USD | -39.47% |
| 1996 | -3.8 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 8.81 Million USD | 195.1% |
| 2024 Q3 | 12.43 Million USD | 41.04% |
| 2024 Q1 | -9.27 Million USD | 25.75% |
| 2023 Q1 | -36.99 Million USD | 28.95% |
| 2023 Q3 | 114.78 Million USD | 356.94% |
| 2023 Q4 | -12.48 Million USD | -110.88% |
| 2023 FY | 20.63 Million USD | 110.7% |
| 2023 Q2 | -44.67 Million USD | -20.77% |
| 2022 FY | -192.83 Million USD | 44.07% |
| 2022 Q4 | -52.06 Million USD | -48.91% |
| 2022 Q1 | -66.87 Million USD | 28.05% |
| 2022 Q2 | -38.94 Million USD | 41.77% |
| 2022 Q3 | -34.96 Million USD | 10.22% |
| 2021 Q1 | -89.2 Million USD | -2.79% |
| 2021 Q2 | -77.49 Million USD | 13.13% |
| 2021 Q4 | -92.94 Million USD | -9.18% |
| 2021 Q3 | -85.12 Million USD | -9.85% |
| 2021 FY | -344.77 Million USD | -26.02% |
| 2020 Q3 | -85.72 Million USD | -68.59% |
| 2020 Q1 | -50.24 Million USD | -32.36% |
| 2020 Q2 | -50.84 Million USD | -1.19% |
| 2020 Q4 | -86.78 Million USD | -1.24% |
| 2020 FY | -273.59 Million USD | -61.84% |
| 2019 FY | -169.05 Million USD | 3.06% |
| 2019 Q4 | -37.96 Million USD | 37.63% |
| 2019 Q3 | -60.86 Million USD | -71.23% |
| 2019 Q2 | -35.54 Million USD | -2.46% |
| 2019 Q1 | -34.68 Million USD | 35.94% |
| 2018 FY | -174.4 Million USD | -46.91% |
| 2018 Q3 | -34.32 Million USD | 22.59% |
| 2018 Q2 | -44.34 Million USD | -6.66% |
| 2018 Q1 | -41.57 Million USD | -33.97% |
| 2018 Q4 | -54.15 Million USD | -57.74% |
| 2017 Q4 | -31.03 Million USD | 1.74% |
| 2017 FY | -118.71 Million USD | -50.33% |
| 2017 Q1 | -27.66 Million USD | -15.14% |
| 2017 Q2 | -28.42 Million USD | -2.74% |
| 2017 Q3 | -31.58 Million USD | -11.12% |
| 2016 Q1 | -13.99 Million USD | 20.68% |
| 2016 Q2 | -16.02 Million USD | -14.52% |
| 2016 FY | -78.96 Million USD | -24.99% |
| 2016 Q3 | -24.92 Million USD | -55.56% |
| 2016 Q4 | -24.02 Million USD | 3.6% |
| 2015 Q3 | -13.82 Million USD | 19.2% |
| 2015 Q1 | -14.6 Million USD | 22.0% |
| 2015 Q2 | -17.11 Million USD | -17.18% |
| 2015 Q4 | -17.64 Million USD | -27.59% |
| 2015 FY | -63.18 Million USD | -13.39% |
| 2014 Q2 | -11.95 Million USD | -57.2% |
| 2014 Q3 | -17.43 Million USD | -45.87% |
| 2014 Q4 | -18.72 Million USD | -7.35% |
| 2014 FY | -55.72 Million USD | -142.62% |
| 2014 Q1 | -7.6 Million USD | 4.65% |
| 2013 Q4 | -7.97 Million USD | -71.62% |
| 2013 Q1 | -3.71 Million USD | -0.64% |
| 2013 Q2 | -6.62 Million USD | -78.48% |
| 2013 Q3 | -4.64 Million USD | 29.89% |
| 2013 FY | -22.96 Million USD | 14.61% |
| 2012 Q1 | -17.38 Million USD | -6566.32% |
| 2012 Q4 | -3.69 Million USD | -35.97% |
| 2012 Q3 | -2.71 Million USD | 12.58% |
| 2012 Q2 | -3.1 Million USD | 82.14% |
| 2012 FY | -26.89 Million USD | -2949.42% |
| 2011 Q1 | -566.08 Thousand USD | -26.76% |
| 2011 FY | -881.97 Thousand USD | 56.27% |
| 2011 Q4 | 268.86 Thousand USD | 202.68% |
| 2011 Q2 | -322.9 Thousand USD | 42.96% |
| 2011 Q3 | -261.84 Thousand USD | 18.91% |
| 2010 Q4 | -446.56 Thousand USD | 13.39% |
| 2010 FY | -2.01 Million USD | -13.84% |
| 2010 Q2 | -525.09 Thousand USD | 0.82% |
| 2010 Q1 | -529.44 Thousand USD | -55.12% |
| 2010 Q3 | -515.63 Thousand USD | 1.8% |
| 2009 Q1 | -557.33 Thousand USD | -1166.61% |
| 2009 Q2 | -477.26 Thousand USD | 14.37% |
| 2009 Q4 | -341.32 Thousand USD | 13.73% |
| 2009 Q3 | -395.64 Thousand USD | 17.1% |
| 2009 FY | -1.77 Million USD | 59.85% |
| 2008 Q2 | -1.46 Million USD | 9.1% |
| 2008 Q3 | -1.38 Million USD | 5.71% |
| 2008 FY | -4.41 Million USD | 63.66% |
| 2008 Q4 | 52.25 Thousand USD | 103.78% |
| 2008 Q1 | -1.61 Million USD | 15.88% |
| 2007 Q4 | -1.91 Million USD | 29.12% |
| 2007 Q1 | -2.59 Million USD | 18.43% |
| 2007 Q2 | -4.92 Million USD | -89.81% |
| 2007 Q3 | -2.7 Million USD | 45.02% |
| 2007 FY | -12.14 Million USD | -21.44% |
| 2006 Q1 | -2.91 Million USD | -10.39% |
| 2006 Q4 | -3.18 Million USD | -61.81% |
| 2006 FY | -10 Million USD | 48.34% |
| 2006 Q2 | -2.35 Million USD | 19.11% |
| 2006 Q3 | -1.96 Million USD | 16.62% |
| 2005 Q1 | -1.45 Million USD | 18.67% |
| 2005 Q2 | -13.39 Million USD | -819.4% |
| 2005 Q3 | -1.86 Million USD | 86.11% |
| 2005 Q4 | -2.63 Million USD | -41.81% |
| 2005 FY | -19.35 Million USD | -215.12% |
| 2004 Q2 | -986.71 Thousand USD | 12.1% |
| 2004 Q1 | -1.12 Million USD | 26.17% |
| 2004 FY | -6.14 Million USD | -29.1% |
| 2004 Q4 | -1.79 Million USD | 20.06% |
| 2004 Q3 | -2.24 Million USD | -127.19% |
| 2003 Q4 | -1.52 Million USD | 25.43% |
| 2003 Q1 | -422.22 Thousand USD | -15.23% |
| 2003 FY | -4.75 Million USD | -206.41% |
| 2003 Q3 | -2.03 Million USD | -162.38% |
| 2003 Q2 | -777.02 Thousand USD | -84.03% |
| 2002 Q4 | -366.4 Thousand USD | 37.71% |
| 2002 FY | -1.55 Million USD | 50.02% |
| 2002 Q3 | -588.24 Thousand USD | -1977.74% |
| 2002 Q2 | 31.32 Thousand USD | 104.98% |
| 2002 Q1 | -629.59 Thousand USD | -12.79% |
| 2001 Q2 | -1.47 Million USD | -486.21% |
| 2001 Q3 | -704.51 Thousand USD | 52.18% |
| 2001 Q4 | -558.19 Thousand USD | 20.77% |
| 2001 FY | -3.1 Million USD | 1.74% |
| 2001 Q1 | -251.33 Thousand USD | -110.85% |
| 2000 Q1 | -1.41 Million USD | -136.41% |
| 2000 Q4 | 2.31 Million USD | 340.51% |
| 2000 Q2 | -3.09 Million USD | -118.4% |
| 2000 Q3 | -963.45 Thousand USD | 68.9% |
| 2000 FY | -3.16 Million USD | -17.13% |
| 1999 Q3 | -500 Thousand USD | 16.67% |
| 1999 FY | -2.7 Million USD | 0.0% |
| 1999 Q4 | -600 Thousand USD | -20.0% |
| 1999 Q1 | -900 Thousand USD | 0.0% |
| 1999 Q2 | -600 Thousand USD | 33.33% |
| 1998 Q3 | -1.2 Million USD | -250.0% |
| 1998 Q1 | -1.3 Million USD | 18.75% |
| 1998 FY | -2.7 Million USD | 49.06% |
| 1998 Q4 | -900 Thousand USD | 25.0% |
| 1998 Q2 | 800 Thousand USD | 161.54% |
| 1997 Q4 | -1.6 Million USD | -60.0% |
| 1997 FY | -5.3 Million USD | -39.47% |
| 1997 Q2 | -1.7 Million USD | -112.5% |
| 1997 Q1 | -800 Thousand USD | 33.33% |
| 1997 Q3 | -1 Million USD | 41.18% |
| 1996 Q4 | -1.2 Million USD | -9.09% |
| 1996 FY | -3.8 Million USD | 0.0% |
| 1996 Q3 | -1.1 Million USD | -83.33% |
| 1996 Q2 | -600 Thousand USD | -700.0% |
| 1996 Q1 | 100 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AbCellera Biologics Inc. | -237.2 Million USD | 108.698% |
| Alkermes plc | 414.12 Million USD | 95.018% |
| Agenus Inc. | -159.54 Million USD | 112.932% |
| Aptorum Group Limited | -10.52 Million USD | 296.069% |
| Ardelyx, Inc. | -63.27 Million USD | 132.608% |
| Dyadic International, Inc. | -8.22 Million USD | 350.713% |
| Eton Pharmaceuticals, Inc. | -1.19 Million USD | 1830.956% |
| Lantern Pharma Inc. | -17.87 Million USD | 215.413% |
| Inhibikase Therapeutics, Inc. | -20.08 Million USD | 202.704% |
| Novavax, Inc. | -566.51 Million USD | 103.642% |
| Janux Therapeutics, Inc. | -72.97 Million USD | 128.273% |
| Pyxis Oncology, Inc. | -82.19 Million USD | 125.102% |
| TransCode Therapeutics, Inc. | -19.41 Million USD | 206.254% |
| Ocuphire Pharma, Inc. | -10.56 Million USD | 295.333% |
| Outlook Therapeutics, Inc. | -53.12 Million USD | 138.838% |
| Madrigal Pharmaceuticals, Inc. | -380.49 Million USD | 105.423% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 184.886% |
| SELLAS Life Sciences Group, Inc. | -37.86 Million USD | 154.485% |
| Syros Pharmaceuticals, Inc. | -128.98 Million USD | 115.996% |
| Barinthus Biotherapeutics plc | -83.91 Million USD | 124.588% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 217.641% |
| Xeris Biopharma Holdings, Inc. | -44.01 Million USD | 146.883% |
| Clearside Biomedical, Inc. | -24.84 Million USD | 183.05% |
| C4 Therapeutics, Inc. | -139.03 Million USD | 114.841% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 107.312% |
| AlloVir, Inc. | -181.33 Million USD | 111.379% |
| Arrowhead Pharmaceuticals, Inc. | -205 Million USD | 110.065% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 170.521% |
| Bicycle Therapeutics plc | -189.94 Million USD | 110.863% |
| BioXcel Therapeutics, Inc. | -171.78 Million USD | 112.011% |
| ChromaDex Corporation | -5.59 Million USD | 468.512% |
| Chimerix, Inc. | -93.06 Million USD | 122.171% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 145.772% |
| Caribou Biosciences, Inc. | -116.05 Million USD | 117.778% |
| CRISPR Therapeutics AG | -222.53 Million USD | 109.272% |
| Precision BioSciences, Inc. | -43.73 Million USD | 147.176% |
| Fate Therapeutics, Inc. | -190.51 Million USD | 110.83% |
| Fortress Biotech, Inc. | -142.34 Million USD | 114.495% |
| Fortress Biotech, Inc. | -142.34 Million USD | 114.495% |
| HOOKIPA Pharma Inc. | -97.69 Million USD | 121.12% |
| ImmuCell Corporation | -5.74 Million USD | 458.955% |
| IDEAYA Biosciences, Inc. | -134.42 Million USD | 115.349% |
| Immix Biopharma, Inc. | -16.14 Million USD | 227.829% |
| Incyte Corporation | 620.52 Million USD | 96.675% |
| Innoviva, Inc. | 176.7 Million USD | 88.324% |
| IO Biotech, Inc. | -91.44 Million USD | 122.564% |
| Jaguar Health, Inc. | -34.29 Million USD | 160.17% |
| Keros Therapeutics, Inc. | -169.94 Million USD | 112.141% |
| Ligand Pharmaceuticals Incorporated | 11.94 Million USD | -72.777% |
| ContextLogic Inc. | -328 Million USD | 106.291% |
| MiMedx Group, Inc. | 37.11 Million USD | 44.409% |
| MEI Pharma, Inc. | 14.54 Million USD | -41.886% |
| NextCure, Inc. | -67.63 Million USD | 130.505% |
| Onconetix, Inc. | -36.03 Million USD | 157.259% |
| Oncternal Therapeutics, Inc. | -41.71 Million USD | 149.463% |
| Opthea Limited | -191.84 Million USD | 110.755% |
| Psyence Biomedical Ltd. | -2.75 Million USD | 849.793% |
| Vaxcyte, Inc. | -468.04 Million USD | 104.408% |
| PDS Biotechnology Corporation | -43.04 Million USD | 147.933% |
| Precigen, Inc. | -88.92 Million USD | 123.203% |
| Pharming Group N.V. | -4.87 Million USD | 522.847% |
| Phathom Pharmaceuticals, Inc. | -167.31 Million USD | 112.332% |
| Pieris Pharmaceuticals, Inc. | -29.75 Million USD | 169.341% |
| PureTech Health plc | -146.19 Million USD | 114.113% |
| Rigel Pharmaceuticals, Inc. | -20.49 Million USD | 200.693% |
| Avidity Biosciences, Inc. | -235.59 Million USD | 108.758% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 184.886% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 107.53% |
| Sol-Gel Technologies Ltd. | -29.3 Million USD | 170.408% |
| Acelyrin, Inc. | -422.06 Million USD | 104.889% |
| Salarius Pharmaceuticals, Inc. | -12.89 Thousand USD | 160108.499% |
| Summit Therapeutics Inc. | -89.73 Million USD | 122.993% |
| Sensei Biotherapeutics, Inc. | -37.06 Million USD | 155.669% |
| Senti Biosciences, Inc. | -92.72 Million USD | 122.251% |
| Stoke Therapeutics, Inc. | -114.77 Million USD | 117.977% |
| Elevation Oncology, Inc. | -45.44 Million USD | 145.402% |
| Alaunos Therapeutics, Inc. | -34.26 Million USD | 160.212% |
| Telomir Pharmaceuticals, Inc. Common Stock | -3.94 Million USD | 623.408% |
| Entrada Therapeutics, Inc. | -3.16 Million USD | 752.53% |
| VistaGen Therapeutics, Inc. | -33.02 Million USD | 162.484% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | 342.713% |
| Wave Life Sciences Ltd. | -67.99 Million USD | 130.344% |
| Seer, Inc. | -103.46 Million USD | 119.942% |
| Verrica Pharmaceuticals Inc. | -65.75 Million USD | 131.377% |
| Aadi Bioscience, Inc. | -71.93 Million USD | 128.684% |
| ESSA Pharma Inc. | -32.13 Million USD | 164.209% |
| GlycoMimetics, Inc. | -39.27 Million USD | 152.534% |
| GT Biopharma, Inc. | -13.57 Million USD | 251.981% |
| Inhibrx Biosciences, Inc. | -219.22 Million USD | 109.412% |
| Akebia Therapeutics, Inc. | -46.25 Million USD | 144.606% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | 76.233% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 136.352% |
| Orchestra BioMed Holdings, Inc. | -51.5 Million USD | 140.059% |
| Alzamend Neuro, Inc. | -9.93 Million USD | 307.625% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 104.091% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | 399.116% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | 140.702% |
| Rocket Pharmaceuticals, Inc. | -259.65 Million USD | 107.946% |
| Aptose Biosciences Inc. | -52.35 Million USD | 139.409% |
| ZyVersa Therapeutics, Inc. | -14.42 Million USD | 243.078% |
| Soligenix, Inc. | -7.69 Million USD | 368.033% |
| Century Therapeutics, Inc. | -146.54 Million USD | 114.08% |
| Kura Oncology, Inc. | -165.8 Million USD | 112.444% |
| TScan Therapeutics, Inc. | -93.45 Million USD | 122.077% |
| Intensity Therapeutics, Inc. | -8.31 Million USD | 348.023% |
| Ocean Biomedical, Inc. | -2.48 Million USD | 931.426% |
| CytomX Therapeutics, Inc. | -6.48 Million USD | 418.214% |
| Autolus Therapeutics plc | -195.02 Million USD | 110.58% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 124.372% |
| EyePoint Pharmaceuticals, Inc. | -73.66 Million USD | 128.01% |
| Eterna Therapeutics Inc. | -21.13 Million USD | 197.625% |
| Adaptive Biotechnologies Corporation | -227.03 Million USD | 109.088% |
| GRI Bio, Inc. | -11.38 Million USD | 281.198% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | 556.915% |
| Tenaya Therapeutics, Inc. | -131.19 Million USD | 115.727% |
| IGM Biosciences, Inc. | -263.46 Million USD | 107.832% |
| INmune Bio, Inc. | -29.74 Million USD | 169.376% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 118.653% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 154.19% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 229.123% |
| Entero Therapeutics, Inc. | -15.77 Million USD | 230.83% |
| Milestone Pharmaceuticals Inc. | -61.09 Million USD | 133.77% |
| X4 Pharmaceuticals, Inc. | -107.52 Million USD | 119.19% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 107.476% |
| Coherus BioSciences, Inc. | -203.19 Million USD | 110.154% |
| Verastem, Inc. | -92.08 Million USD | 122.407% |
| Abeona Therapeutics Inc. | -47.13 Million USD | 143.774% |
| Pliant Therapeutics, Inc. | -184.14 Million USD | 111.205% |
| Tonix Pharmaceuticals Holding Corp. | -118.38 Million USD | 117.429% |
| Histogen Inc. | -10.64 Million USD | 293.865% |
| Aprea Therapeutics, Inc. | -15.47 Million USD | 233.357% |
| Surrozen, Inc. | -45.78 Million USD | 145.07% |
| Organovo Holdings, Inc. | -15.08 Million USD | 236.769% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | 505.345% |
| Ovid Therapeutics Inc. | -59.28 Million USD | 134.805% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 140.225% |
| CASI Pharmaceuticals, Inc. | -25.28 Million USD | 181.618% |
| Cadrenal Therapeutics, Inc. Common Stock | -7.63 Million USD | 370.319% |
| Centessa Pharmaceuticals plc | -171.28 Million USD | 112.046% |
| Hepion Pharmaceuticals, Inc. | -48.44 Million USD | 142.588% |
| Arcturus Therapeutics Holdings Inc. | -78.2 Million USD | 126.383% |
| BioRestorative Therapies, Inc. | -15.22 Million USD | 235.558% |
| Apollomics, Inc. | -54.83 Million USD | 137.628% |
| Amarin Corporation plc | -67.58 Million USD | 130.528% |
| Mesoblast Limited | -58.79 Million USD | 135.094% |
| Turnstone Biologics Corp. | -59.03 Million USD | 134.952% |
| Kymera Therapeutics, Inc. | -165.53 Million USD | 112.465% |
| Synaptogenix, Inc. | -8.31 Million USD | 348.176% |
| Tiziana Life Sciences Ltd | -14.58 Million USD | 241.458% |
| Aurinia Pharmaceuticals Inc. | -91.69 Million USD | 122.503% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 530.62% |
| Monopar Therapeutics Inc. | -8.83 Million USD | 333.637% |
| Exelixis, Inc. | 170.88 Million USD | 87.926% |
| Better Therapeutics, Inc. | -38.26 Million USD | 153.926% |
| Nurix Therapeutics, Inc. | -155.06 Million USD | 113.306% |
| Apellis Pharmaceuticals, Inc. | -517.12 Million USD | 103.99% |
| NLS Pharmaceutics AG | -11.8 Million USD | 274.751% |
| Dermata Therapeutics, Inc. | -8.04 Million USD | 356.569% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | 168.793% |
| Gritstone bio, Inc. | -154.63 Million USD | 113.343% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 129.963% |
| TNF Pharmaceuticals, Inc. | -17.12 Million USD | 220.498% |
| Avid Bioservices, Inc. | -18.67 Million USD | 210.467% |
| Insmed Incorporated | -709.62 Million USD | 102.908% |
| Virpax Pharmaceuticals, Inc. | -15.68 Million USD | 231.506% |
| MediWound Ltd. | -15.29 Million USD | 234.944% |
| OmniAb, Inc. | -69.41 Million USD | 129.722% |
| Alector, Inc. | -151.74 Million USD | 113.598% |
| Seres Therapeutics, Inc. | -107.98 Million USD | 119.108% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 139.566% |
| Zai Lab Limited | -366.57 Million USD | 105.629% |
| Revance Therapeutics, Inc. | -316.77 Million USD | 106.513% |
| Aura Biosciences, Inc. | -84.99 Million USD | 124.277% |
| Lyell Immunopharma, Inc. | -245.49 Million USD | 108.405% |
| Immunic, Inc. | -99.22 Million USD | 120.795% |
| Tarsus Pharmaceuticals, Inc. | -143.15 Million USD | 114.413% |
| Veracyte, Inc. | -85.79 Million USD | 124.049% |
| InMed Pharmaceuticals Inc. | - USD | -Infinity% |
| FibroGen, Inc. | -281.81 Million USD | 107.321% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 245.201% |
| Adial Pharmaceuticals, Inc. | -6.88 Million USD | 399.552% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.79 Million USD | 209.793% |
| Jazz Pharmaceuticals plc | 578.58 Million USD | 96.434% |
| Cyclacel Pharmaceuticals, Inc. | -25.45 Million USD | 181.063% |
| Amylyx Pharmaceuticals, Inc. | 38.8 Million USD | 46.825% |
| Galecto, Inc. | -39.9 Million USD | 151.705% |
| Calithera Biosciences, Inc. | -42.07 Million USD | 149.04% |
| Fortrea Holdings Inc. | 63.1 Million USD | 67.301% |
| KalVista Pharmaceuticals, Inc. | -140.44 Million USD | 114.691% |
| Aptevo Therapeutics Inc. | -28.87 Million USD | 171.449% |
| XBiotech Inc. | -37.51 Million USD | 155.007% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 129.963% |
| Lyra Therapeutics, Inc. | -67.12 Million USD | 130.74% |
| Foghorn Therapeutics Inc. | -107.9 Million USD | 119.121% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 180.372% |
| Theravance Biopharma, Inc. | -53.29 Million USD | 138.717% |
| Ultragenyx Pharmaceutical Inc. | -569.2 Million USD | 103.625% |
| Metagenomi, Inc. Common Stock | -78.49 Million USD | 126.287% |
| Vaxxinity, Inc. | -58.28 Million USD | 135.4% |
| BioCryst Pharmaceuticals, Inc. | -103.7 Million USD | 119.895% |
| Gain Therapeutics, Inc. | -22.25 Million USD | 192.72% |
| Cartesian Therapeutics, Inc. | -86.41 Million USD | 123.876% |
| NexImmune, Inc. | -29.19 Million USD | 170.679% |
| Creative Medical Technology Holdings, Inc. | -5.62 Million USD | 467.127% |
| Marker Therapeutics, Inc. | -14.58 Million USD | 241.502% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 99.49% |
| Chemomab Therapeutics Ltd. | -25.45 Million USD | 181.044% |
| Scopus BioPharma Inc. | -11.71 Million USD | 276.126% |
| RAPT Therapeutics, Inc. | -127.06 Million USD | 116.239% |
| Ainos, Inc. | -13.2 Million USD | 256.235% |
| Pluri Inc. | -22.15 Million USD | 193.118% |
| Prothena Corporation plc | -191.03 Million USD | 110.801% |
| Adaptimmune Therapeutics plc | -138.03 Million USD | 114.947% |
| Celularity Inc. | -192.28 Million USD | 110.73% |
| Rallybio Corporation | -78.93 Million USD | 126.14% |
| Cue Biopharma, Inc. | -52.14 Million USD | 139.565% |
| MeiraGTx Holdings plc | -137.06 Million USD | 115.054% |
| Omeros Corporation | -164.53 Million USD | 112.541% |
| Humacyte, Inc. | -100.04 Million USD | 120.623% |
| Immunocore Holdings plc | -59.64 Million USD | 134.591% |
| Cocrystal Pharma, Inc. | -18.55 Million USD | 211.175% |
| Cidara Therapeutics, Inc. | -24.48 Million USD | 184.275% |
| Blueprint Medicines Corporation | -486.27 Million USD | 104.243% |
| CalciMedica, Inc. | -21.87 Million USD | 194.322% |
| Cabaletta Bio, Inc. | -74.66 Million USD | 127.636% |
| Marinus Pharmaceuticals, Inc. | -131.48 Million USD | 115.692% |
| Scholar Rock Holding Corporation | -171.29 Million USD | 112.045% |
| Sana Biotechnology, Inc. | -326.9 Million USD | 106.312% |
| Pulmatrix, Inc. | -14.74 Million USD | 239.98% |
| Elicio Therapeutics, Inc. | -35.74 Million USD | 157.723% |
| Vigil Neuroscience, Inc. | -88.86 Million USD | 123.218% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 104.004% |
| Adlai Nortye Ltd. American Depositary Shares | -67.55 Million USD | 130.544% |
| Cytokinetics, Incorporated | -496.2 Million USD | 104.158% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | 159.947% |
| Nutriband Inc. | -4.87 Million USD | 523.508% |
| Protara Therapeutics, Inc. | -43.61 Million USD | 147.309% |
| Vor Biopharma Inc. | -126.03 Million USD | 116.371% |
| Roivant Sciences Ltd. | 4.24 Billion USD | 99.514% |
| Evogene Ltd. | -26.39 Million USD | 178.182% |
| ProKidney Corp. | -151.52 Million USD | 113.617% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 131.972% |
| Hoth Therapeutics, Inc. | -7.69 Million USD | 368.231% |
| BridgeBio Pharma, Inc. | -607.37 Million USD | 103.397% |
| CorMedix Inc. | -48.95 Million USD | 142.144% |
| BioLineRx Ltd. | -49.69 Million USD | 141.52% |
| Tango Therapeutics, Inc. | -114.17 Million USD | 118.072% |
| Galectin Therapeutics Inc. | -38.07 Million USD | 154.195% |
| Atai Life Sciences N.V. | -125.47 Million USD | 116.444% |
| Renovaro Biosciences Inc. | -81.63 Million USD | 125.273% |
| Aerovate Therapeutics, Inc. | -81.4 Million USD | 125.345% |
| Zentalis Pharmaceuticals, Inc. | -248.98 Million USD | 108.287% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 167.121% |
| MediciNova, Inc. | -9.9 Million USD | 308.409% |
| Praxis Precision Medicines, Inc. | -126.37 Million USD | 116.327% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | 384.889% |
| GeoVax Labs, Inc. | -26.74 Million USD | 177.153% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 108.9% |
| Biomea Fusion, Inc. | -126.13 Million USD | 116.358% |
| PTC Therapeutics, Inc. | -349.4 Million USD | 105.905% |
| Mereo BioPharma Group plc | -28.41 Million USD | 172.611% |
| Cullinan Oncology, Inc. | -191.08 Million USD | 110.798% |
| Syndax Pharmaceuticals, Inc. | -229.95 Million USD | 108.973% |
| Absci Corporation | -115.51 Million USD | 117.862% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 174.792% |
| 4D Molecular Therapeutics, Inc. | -112.86 Million USD | 118.281% |
| Dyne Therapeutics, Inc. | -242.16 Million USD | 108.52% |
| Kiniksa Pharmaceuticals, Ltd. | -25.19 Million USD | 181.89% |
| Ventyx Biosciences, Inc. | -207.99 Million USD | 109.92% |
| Allakos Inc. | -196.05 Million USD | 110.524% |
| Imunon, Inc. | -21.03 Million USD | 198.11% |
| Fulcrum Therapeutics, Inc. | -110.66 Million USD | 118.645% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 80.768% |
| BioAtla, Inc. | -129.68 Million USD | 115.91% |
| NLS Pharmaceutics AG | -11.8 Million USD | 274.751% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | 230.234% |
| Allogene Therapeutics, Inc. | -327.73 Million USD | 106.296% |
| Larimar Therapeutics, Inc. | -41.75 Million USD | 149.411% |
| XOMA Corporation | -41.84 Million USD | 149.305% |
| Kezar Life Sciences, Inc. | -105.23 Million USD | 119.606% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 116.983% |
| aTyr Pharma, Inc. | -54.91 Million USD | 137.57% |
| Aligos Therapeutics, Inc. | -87.42 Million USD | 123.6% |
| Akero Therapeutics, Inc. | -172.87 Million USD | 111.936% |
| Viridian Therapeutics, Inc. | -254.45 Million USD | 108.109% |
| Eliem Therapeutics, Inc. | -21.46 Million USD | 196.119% |
| EyeGate Pharmaceuticals, Inc. | -8.21 Million USD | 351.231% |
| Akari Therapeutics, Plc | -16.8 Million USD | 222.772% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | 233425.003% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 93.888% |
| Lexaria Bioscience Corp. | -6.53 Million USD | 415.778% |
| UroGen Pharma Ltd. | -65.53 Million USD | 131.483% |
| Sutro Biopharma, Inc. | -89.27 Million USD | 123.111% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 384.083% |
| Orgenesis Inc. | -53.63 Million USD | 138.469% |
| Entera Bio Ltd. | -8.89 Million USD | 332.066% |
| GH Research PLC | -41.22 Million USD | 150.053% |
| Lisata Therapeutics, Inc. | -25.7 Million USD | 180.259% |
| Reneo Pharmaceuticals, Inc. | -83.05 Million USD | 124.843% |
| Xencor, Inc. | -138.63 Million USD | 114.883% |
| 60 Degrees Pharmaceuticals, Inc. | -5.15 Million USD | 500.285% |
| Replimune Group, Inc. | -234.77 Million USD | 108.788% |
| Coeptis Therapeutics Holdings, Inc. | -21.49 Million USD | 196.007% |
| Vanda Pharmaceuticals Inc. | -13.95 Million USD | 247.886% |
| Lexaria Bioscience Corp. | -6.53 Million USD | 415.778% |
| Portage Biotech Inc. | -18.25 Million USD | 213.039% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | 384.889% |
| Olema Pharmaceuticals, Inc. | -104.96 Million USD | 119.658% |
| OncoCyte Corporation | -25.13 Million USD | 182.085% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | 282.514% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | 280.09% |
| Purple Biotech Ltd. | 22.27 Million USD | 7.355% |
| CollPlant Biotechnologies Ltd. | -7.51 Million USD | 374.667% |
| scPharmaceuticals Inc. | -55.39 Million USD | 137.246% |
| ProMIS Neurosciences, Inc. | -18.89 Million USD | 209.183% |
| HilleVax, Inc. | -133.34 Million USD | 115.473% |
| NeuroSense Therapeutics Ltd. | -12.04 Million USD | 271.242% |
| Tharimmune, Inc. | -9.45 Million USD | 318.218% |
| Genprex, Inc. | -31.07 Million USD | 166.396% |
| Neumora Therapeutics, Inc. Common Stock | -188.19 Million USD | 110.964% |
| Atossa Therapeutics, Inc. | -31.37 Million USD | 165.758% |
| XTL Biopharmaceuticals Ltd. | -765 Thousand USD | 2797.124% |
| Virios Therapeutics, Inc. | -5.44 Million USD | 478.801% |
| OKYO Pharma Limited | -15.74 Thousand USD | 131105.42% |
| Savara Inc. | -60 Million USD | 134.384% |
| Curis, Inc. | -48.33 Million USD | 142.69% |
| Daré Bioscience, Inc. | -30.83 Million USD | 166.904% |
| Carmell Therapeutics Corporation | -5.21 Million USD | 495.474% |
| Titan Pharmaceuticals, Inc. | -7.27 Million USD | 383.537% |
| Achieve Life Sciences, Inc. | -27.25 Million USD | 175.717% |
| BeiGene, Ltd. | -1.2 Billion USD | 101.708% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | 203.479% |
| Revolution Medicines, Inc. Warrant | -487.18 Million USD | 104.235% |
| Protagonist Therapeutics, Inc. | -93.65 Million USD | 122.032% |
| Erasca, Inc. | -141.52 Million USD | 114.579% |
| bluebird bio, Inc. | -244.26 Million USD | 108.447% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | 555.779% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 89.389% |
| DBV Technologies S.A. | -76.43 Million USD | 126.995% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | 555.779% |
| Moderna, Inc. | -4.23 Billion USD | 100.487% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 148.424% |
| Fresh Tracks Therapeutics, Inc. | -6.36 Million USD | 424.418% |
| Molecular Templates, Inc. | -10.46 Million USD | 297.143% |
| Acrivon Therapeutics, Inc. Common Stock | -67.23 Million USD | 130.687% |
| Travere Therapeutics, Inc. | -376.74 Million USD | 105.477% |
| Monte Rosa Therapeutics, Inc. | -143.31 Million USD | 114.397% |
| Spruce Biosciences, Inc. | -51.99 Million USD | 139.684% |
| Celldex Therapeutics, Inc. | -154.54 Million USD | 113.351% |
| Cogent Biosciences, Inc. | -208.13 Million USD | 109.914% |
| MacroGenics, Inc. | -168.24 Million USD | 112.264% |
| RenovoRx, Inc. | -11.39 Million USD | 281.055% |
| Adicet Bio, Inc. | -152.03 Million USD | 113.571% |
| Prime Medicine, Inc. | -191.29 Million USD | 110.786% |
| Aditxt, Inc. | -26.06 Million USD | 179.168% |
| Adagene Inc. | -23.71 Million USD | 186.986% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 382.253% |
| Quantum-Si incorporated | -111.17 Million USD | 118.56% |
| Maravai LifeSciences Holdings, Inc. | -31.64 Million USD | 165.195% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 241.537% |
| Voyager Therapeutics, Inc. | 122.01 Million USD | 83.09% |
| SciSparc Ltd. | -5.77 Million USD | 457.405% |
| Vericel Corporation | -6.46 Million USD | 419.199% |
| Revelation Biosciences, Inc. | -8.65 Million USD | 338.348% |
| Minerva Neurosciences, Inc. | -23.11 Million USD | 189.245% |
| Generation Bio Co. | -138.56 Million USD | 114.891% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 124.85% |
| Black Diamond Therapeutics, Inc. | -86.46 Million USD | 123.864% |
| Arcutis Biotherapeutics, Inc. | -241.1 Million USD | 108.558% |
| Invivyd, Inc. | -207.78 Million USD | 109.93% |
| Relay Therapeutics, Inc. | -373 Million USD | 105.532% |
| Quoin Pharmaceuticals, Ltd. | -9.37 Million USD | 320.003% |
| Spero Therapeutics, Inc. | 21.48 Million USD | 3.948% |
| Artelo Biosciences, Inc. | -10.28 Million USD | 300.574% |
| 2seventy bio, Inc. | -216.7 Million USD | 109.521% |
| ADMA Biologics, Inc. | 21.63 Million USD | 4.618% |
| Clene Inc. | -40.54 Million USD | 150.895% |
| Capricor Therapeutics, Inc. | -24.07 Million USD | 185.693% |
| Boundless Bio, Inc. Common Stock | -54.79 Million USD | 137.654% |
| GeoVax Labs, Inc. | -26.74 Million USD | 177.153% |
| Recursion Pharmaceuticals, Inc. | -350.06 Million USD | 105.894% |
| Citius Pharmaceuticals, Inc. | -36.73 Million USD | 156.172% |
| Contineum Therapeutics, Inc. Class A Common Stock | 16.07 Million USD | -28.339% |
| Relmada Therapeutics, Inc. | -103.7 Million USD | 119.896% |
| Finch Therapeutics Group, Inc. | -34 Million USD | 160.682% |
| ALX Oncology Holdings Inc. | -170.27 Million USD | 112.117% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 103.015% |
| Evaxion Biotech A/S | -22.19 Million USD | 192.954% |
| Ocular Therapeutix, Inc. | -82.38 Million USD | 125.046% |
| Verve Therapeutics, Inc. | -223.12 Million USD | 109.247% |
| Trevena, Inc. | -35.28 Million USD | 158.47% |
| Surrozen, Inc. | -45.78 Million USD | 145.07% |
| Tyra Biosciences, Inc. | -79.94 Million USD | 125.809% |
| Cingulate Inc. | -22.75 Million USD | 190.658% |
| Galmed Pharmaceuticals Ltd. | 7.49 Million USD | -175.4% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 146.193% |
| Tenax Therapeutics, Inc. | -8.23 Million USD | 350.585% |
| Terns Pharmaceuticals, Inc. | -102.55 Million USD | 120.118% |
| ACADIA Pharmaceuticals Inc. | -73.37 Million USD | 128.118% |
| Connect Biopharma Holdings Limited | -62.07 Million USD | 133.239% |
| Clearmind Medicine Inc. | -8.74 Million USD | 336.039% |
| Kronos Bio, Inc. | -121.83 Million USD | 116.936% |
| Bolt Biotherapeutics, Inc. | -76.19 Million USD | 127.079% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | 803.481% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 120.464% |
| Statera Biopharma, Inc. | -98.34 Million USD | 120.98% |
| ImmunityBio, Inc. | -362.25 Million USD | 105.696% |
| Korro Bio, Inc. | -84.53 Million USD | 124.408% |
| Kineta, Inc. | -15.72 Million USD | 231.228% |
| BioVie Inc. | -32.17 Million USD | 164.118% |
| Codexis, Inc. | -68.06 Million USD | 130.312% |
| Celularity Inc. | -192.28 Million USD | 110.73% |
| Crinetics Pharmaceuticals, Inc. | -222.6 Million USD | 109.269% |
| Celcuity Inc. | -66.23 Million USD | 131.153% |
| Virax Biolabs Group Limited | -6.49 Million USD | 417.603% |
| Cibus, Inc. | -318.88 Million USD | 106.47% |
| Eledon Pharmaceuticals, Inc. | -43 Million USD | 147.984% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | 160.965% |
| IN8bio, Inc. | -30.33 Million USD | 168.013% |
| Kodiak Sciences Inc. | -277.32 Million USD | 107.44% |
| Annexon, Inc. | -143.72 Million USD | 114.356% |
| Adverum Biotechnologies, Inc. | -123.79 Million USD | 116.668% |
| Assembly Biosciences, Inc. | -64.64 Million USD | 131.917% |
| Avalo Therapeutics, Inc. | -23.44 Million USD | 188.01% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 105.833% |
| Eyenovia, Inc. | -25.4 Million USD | 181.212% |
| Puma Biotechnology, Inc. | 32.64 Million USD | 36.786% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | 470.964% |
| Xilio Therapeutics, Inc. | -79.13 Million USD | 126.074% |
| Arcellx, Inc. | -89.88 Million USD | 122.956% |
| Cardiff Oncology, Inc. | -45.41 Million USD | 145.435% |
| Enanta Pharmaceuticals, Inc. | -137.2 Million USD | 115.038% |
| Regulus Therapeutics Inc. | -31.1 Million USD | 166.325% |
| Moolec Science SA | -6.65 Million USD | 410.093% |
| Acumen Pharmaceuticals, Inc. | -61.13 Million USD | 133.748% |
| Geron Corporation | -193.94 Million USD | 110.639% |
| LAVA Therapeutics N.V. | -43.25 Million USD | 147.703% |
| Royalty Pharma plc | 1.49 Billion USD | 98.617% |
| Atea Pharmaceuticals, Inc. | -164.16 Million USD | 112.569% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | 321.197% |
| TFF Pharmaceuticals, Inc. | -21.89 Million USD | 194.238% |
| Mersana Therapeutics, Inc. | -170.95 Million USD | 112.069% |
| Humacyte, Inc. | -100.04 Million USD | 120.623% |
| Structure Therapeutics Inc. | -102.77 Million USD | 120.076% |
| 89bio, Inc. | -151.2 Million USD | 113.646% |
| PMV Pharmaceuticals, Inc. | -80.13 Million USD | 125.749% |
| Avenue Therapeutics, Inc. | -14.54 Million USD | 241.905% |
| Genelux Corporation | -24.16 Million USD | 185.384% |
| Trevi Therapeutics, Inc. | -33.92 Million USD | 160.823% |
| Lexicon Pharmaceuticals, Inc. | -171.75 Million USD | 112.013% |
| Notable Labs, Ltd. | -14.65 Million USD | 240.772% |
| Liquidia Corporation | -73.38 Million USD | 128.116% |
| Mustang Bio, Inc. | -50.72 Million USD | 140.675% |
| Immunovant, Inc. | -282.7 Million USD | 107.298% |
| Quantum-Si incorporated | -111.17 Million USD | 118.56% |
| Arbutus Biopharma Corporation | -78.1 Million USD | 126.418% |
| DiaMedica Therapeutics Inc. | -21.26 Million USD | 197.019% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 120.226% |
| Acasti Pharma Inc. | -11.31 Million USD | 282.399% |
| MiNK Therapeutics, Inc. | -22.92 Million USD | 190.017% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 229.123% |
| Xenon Pharmaceuticals Inc. | -214.05 Million USD | 109.639% |
| Elevai Labs, Inc. Common Stock | -3.66 Million USD | 662.349% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | 229.882% |
| Tempest Therapeutics, Inc. | -29.15 Million USD | 170.765% |
| Soleno Therapeutics, Inc. | -41.38 Million USD | 149.857% |
| PepGen Inc. | -84.76 Million USD | 124.341% |
| Moleculin Biotech, Inc. | -29.63 Million USD | 169.633% |
| United Therapeutics Corporation | 1.18 Billion USD | 98.259% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 190.112% |
| Solid Biosciences Inc. | -104.31 Million USD | 119.78% |
| BriaCell Therapeutics Corp. | -32.8 Million USD | 162.89% |
| Immuneering Corporation | -58.41 Million USD | 135.323% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | 505.345% |
| Silo Pharma, Inc. | -3.85 Million USD | 635.145% |
| Belite Bio, Inc | -31.66 Million USD | 165.154% |
| XOMA Corporation | -41.84 Million USD | 149.305% |
| ARS Pharmaceuticals, Inc. | -67.52 Million USD | 130.558% |
| Bionomics Limited | -17.89 Billion USD | 100.115% |
| Apogee Therapeutics, Inc. | -93 Million USD | 122.185% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | 42.172% |
| uniQure N.V. | -282.87 Million USD | 107.294% |
| Cassava Sciences, Inc. | -105.95 Million USD | 119.473% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 382.253% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 115.932% |
| Forte Biosciences, Inc. | -32.48 Million USD | 163.514% |
| Anebulo Pharmaceuticals, Inc. | -8.3 Million USD | 348.328% |
| Enlivex Therapeutics Ltd. | -29.39 Million USD | 170.192% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | 470.964% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 245.201% |
| FibroBiologics, Inc. Common Stock | -8.88 Million USD | 332.118% |
| Altimmune, Inc. | -95.92 Million USD | 121.509% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 128.074% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | 42.172% |
| Compugen Ltd. | -12.99 Million USD | 258.813% |
| Peak Bio, Inc. | -1356.23 USD | 1521449.624% |
| Zevra Therapeutics, Inc. | -49.6 Million USD | 141.595% |
| Benitec Biopharma Inc. | -22.49 Million USD | 191.743% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 108.515% |
| NKGen Biotech, Inc. Common Stock | -29.74 Million USD | 169.364% |
| Zura Bio Limited | -62.63 Million USD | 132.94% |
| PolyPid Ltd. | -22.86 Million USD | 190.23% |
| Aileron Therapeutics, Inc. | -16.27 Million USD | 226.769% |
| NKGen Biotech, Inc. Warrants | -29.74 Million USD | 169.364% |
| Instil Bio, Inc. | -159.16 Million USD | 112.963% |
| argenx SE | -425.04 Million USD | 104.854% |
| Immunome, Inc. | -109.53 Million USD | 118.838% |
| Compass Therapeutics, Inc. | -50.36 Million USD | 140.969% |
| Verona Pharma plc | -67.83 Million USD | 130.418% |
| enGene Holdings Inc. Warrants | -26.06 Million USD | 179.175% |
| Shattuck Labs, Inc. | -91.95 Million USD | 122.438% |
| CervoMed Inc. | -7.81 Million USD | 364.089% |
| LENZ Therapeutics, Inc. | -73.11 Million USD | 128.222% |
| Plus Therapeutics, Inc. | -13.32 Million USD | 254.891% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 142.83% |
| Moolec Science SA | -6.65 Million USD | 410.093% |
| Enveric Biosciences, Inc. | -16.44 Million USD | 225.44% |
| Inovio Pharmaceuticals, Inc. | -135.22 Million USD | 115.258% |
| AnaptysBio, Inc. | -164.41 Million USD | 112.55% |
| Design Therapeutics, Inc. | -78.19 Million USD | 126.388% |
| Leap Therapeutics, Inc. | -87.04 Million USD | 123.705% |
| NeurAxis, Inc. | -6.66 Million USD | 409.596% |
| Seelos Therapeutics, Inc. | -40.49 Million USD | 150.947% |
| Lumos Pharma, Inc. | -36.61 Million USD | 156.353% |
| Achilles Therapeutics plc | -75.25 Million USD | 127.417% |
| enGene Holdings Inc. Common Stock | -26.06 Million USD | 179.175% |
| 180 Life Sciences Corp. | -13.47 Million USD | 253.092% |
| Opiant Pharmaceuticals, Inc. | 5.15 Million USD | -300.15% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | 803.481% |
| Nutriband Inc. | -4.87 Million USD | 523.508% |
| ORIC Pharmaceuticals, Inc. | -110.78 Million USD | 118.625% |
| CG Oncology, Inc. Common stock | -55.44 Million USD | 137.211% |
| Fractyl Health, Inc. Common Stock | -50.83 Million USD | 140.587% |
| Rani Therapeutics Holdings, Inc. | -66.09 Million USD | 131.215% |
| MoonLake Immunotherapeutics | -54.12 Million USD | 138.122% |
| Palisade Bio, Inc. | -13.07 Million USD | 257.865% |
| Tourmaline Bio, Inc. | -45.4 Million USD | 145.438% |
| Beam Therapeutics Inc. | -176.48 Million USD | 111.691% |
| Neurogene Inc. | -55.58 Million USD | 137.121% |
| Mirum Pharmaceuticals, Inc. | -109.15 Million USD | 118.903% |
| AEON Biopharma, Inc. | -48.42 Million USD | 142.605% |
| CARGO Therapeutics, Inc. Common Stock | -96.71 Million USD | 121.335% |
| Sesen Bio, Inc. | -25.9 Million USD | 179.636% |
| Enliven Therapeutics, Inc. | -83.52 Million USD | 124.702% |
| Kiora Pharmaceuticals, Inc. | -12.58 Million USD | 263.924% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 104.48% |
| Taysha Gene Therapies, Inc. | -72.43 Million USD | 128.483% |
| Athira Pharma, Inc. | -125.46 Million USD | 116.445% |
| Vaccinex, Inc. | -22.88 Million USD | 190.159% |
| HCW Biologics Inc. | -25.71 Million USD | 180.23% |
| XOMA Corporation | -41.84 Million USD | 149.305% |
| Nektar Therapeutics | -137.42 Million USD | 115.014% |
| Arvinas, Inc. | -401.5 Million USD | 105.139% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | 233425.003% |
| Merus N.V. | -156.54 Million USD | 113.18% |
| Omega Therapeutics, Inc. | -100.26 Million USD | 120.579% |
| Quince Therapeutics, Inc. | -34.62 Million USD | 159.598% |
| Rezolute, Inc. | -70.42 Million USD | 129.299% |
| Clene Inc. | -40.54 Million USD | 150.895% |
| Indaptus Therapeutics, Inc. | -16.37 Million USD | 225.976% |
| BeyondSpring Inc. | -23.11 Million USD | 189.266% |
| Synlogic, Inc. | -55.16 Million USD | 137.405% |
| Allarity Therapeutics, Inc. | -17.92 Million USD | 215.082% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | 290.623% |
| Peak Bio, Inc. | -1356.23 USD | 1521449.624% |
| Werewolf Therapeutics, Inc. | -40.5 Million USD | 150.942% |
| Krystal Biotech, Inc. | -109.72 Million USD | 118.804% |
| Karyopharm Therapeutics Inc. | -129.53 Million USD | 115.928% |
| SpringWorks Therapeutics, Inc. | -343.01 Million USD | 106.015% |
| Lipella Pharmaceuticals Inc. | -4.74 Million USD | 534.749% |
| MannKind Corporation | 8.67 Million USD | -137.762% |
| Ikena Oncology, Inc. | -75.41 Million USD | 127.359% |
| Cyclerion Therapeutics, Inc. | -9.64 Million USD | 313.88% |
| Gyre Therapeutics, Inc. | -67.23 Million USD | 130.69% |
| Gossamer Bio, Inc. | -183.75 Million USD | 111.228% |
| CohBar, Inc. | -12.38 Million USD | 266.552% |
| Cognition Therapeutics, Inc. | -50.72 Million USD | 140.677% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 174.792% |
| Legend Biotech Corporation | -439.48 Million USD | 104.695% |
| Mural Oncology plc | -194.63 Million USD | 110.601% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 130.73% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 227.796% |
| Disc Medicine, Inc. | -91.12 Million USD | 122.643% |
| Champions Oncology, Inc. | -7.35 Million USD | 380.492% |
| REGENXBIO Inc. | -268.12 Million USD | 107.695% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | 292.505% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 137.006% |
| Cellectar Biosciences, Inc. | -38.96 Million USD | 152.959% |
| Edgewise Therapeutics, Inc. | -114.35 Million USD | 118.043% |
| Vaxart, Inc. | -83.34 Million USD | 124.756% |
| PharmaCyte Biotech, Inc. | -8.52 Million USD | 342.171% |
| Aldeyra Therapeutics, Inc. | -42.79 Million USD | 148.215% |
| Cellectis S.A. | -106.62 Million USD | 119.351% |
| Longeveron Inc. | -21.02 Million USD | 198.117% |
| Repare Therapeutics Inc. | -116.22 Million USD | 117.753% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 107.704% |
| Inozyme Pharma, Inc. | -75.64 Million USD | 127.276% |
| Revolution Medicines, Inc. | -487.18 Million USD | 104.235% |
| Nymox Pharmaceutical Corporation | -6.65 Million USD | 410.177% |
| Third Harmonic Bio, Inc. | -43.95 Million USD | 146.942% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 127.662% |
| AN2 Therapeutics, Inc. | -69.63 Million USD | 129.63% |
| Anixa Biosciences, Inc. | -11.01 Million USD | 287.385% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 99.521% |
| Denali Therapeutics Inc. | -196.69 Million USD | 110.49% |
| Revelation Biosciences, Inc. | -8.65 Million USD | 338.348% |
| Veru Inc. | -93.78 Million USD | 122.001% |
| Corvus Pharmaceuticals, Inc. | -23.32 Million USD | 188.444% |
| Cingulate Inc. | -22.75 Million USD | 190.658% |
| Passage Bio, Inc. | -108.38 Million USD | 119.036% |
| Context Therapeutics Inc. | -25.07 Million USD | 182.293% |
| Exicure, Inc. | -14.99 Million USD | 237.59% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 110.013% |
| Oramed Pharmaceuticals Inc. | -40.59 Million USD | 150.823% |
| Scinai Immunotherapeutics Ltd. | -9.71 Million USD | 312.341% |
| Rhythm Pharmaceuticals, Inc. | -184.35 Million USD | 111.192% |
| Nuvalent, Inc. | -149.49 Million USD | 113.802% |
| ABVC BioPharma, Inc. | -8.21 Million USD | 351.116% |
| Carisma Therapeutics, Inc. | -88.73 Million USD | 123.253% |
| Unicycive Therapeutics, Inc. | -20.77 Million USD | 199.321% |
| OmniAb, Inc. | -69.41 Million USD | 129.722% |
| Anew Medical, Inc. | -1.3 Million USD | 1686.129% |
| Fennec Pharmaceuticals Inc. | -12.77 Million USD | 261.561% |
| Lipocine Inc. | -17.93 Million USD | 215.069% |
| Lexeo Therapeutics, Inc. Common Stock | -68.51 Million USD | 130.115% |
| Nautilus Biotechnology, Inc. | -76.15 Million USD | 127.094% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 154.19% |
| G1 Therapeutics, Inc. | -39.52 Million USD | 152.2% |
| Bellerophon Therapeutics, Inc. | -22.38 Million USD | 192.177% |
| Sage Therapeutics, Inc. | -579.84 Million USD | 103.558% |
| Ocugen, Inc. | -65.53 Million USD | 131.486% |
| Mind Medicine (MindMed) Inc. | -93.86 Million USD | 121.981% |
| Q32 Bio Inc. | -92.1 Million USD | 122.402% |
| Brainstorm Cell Therapeutics Inc. | -21.43 Million USD | 196.24% |
| Alumis Inc. Common Stock | -158.17 Million USD | 113.044% |
| Equillium, Inc. | -14.52 Million USD | 242.081% |
| Kyverna Therapeutics, Inc. | -62.4 Million USD | 133.063% |
| Coya Therapeutics, Inc. | -7.9 Million USD | 361.067% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | 209.371% |
| Galera Therapeutics, Inc. | -46.95 Million USD | 143.946% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 119.023% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | 272.372% |
| Dominari Holdings Inc. | -21.79 Million USD | 194.664% |
| Edesa Biotech, Inc. | -9.22 Million USD | 323.718% |
| vTv Therapeutics Inc. | -25.5 Million USD | 180.907% |
| Bio-Techne Corporation | 206.68 Million USD | 90.017% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 105.27% |
| Harmony Biosciences Holdings, Inc. | 192.03 Million USD | 89.255% |
| Prelude Therapeutics Incorporated | -132.27 Million USD | 115.598% |
| Candel Therapeutics, Inc. | -38.39 Million USD | 153.744% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 113.655% |
| Nkarta, Inc. | -131.65 Million USD | 115.673% |
| BioCardia, Inc. | -11.64 Million USD | 277.199% |
| Iterum Therapeutics plc | -47.46 Million USD | 143.467% |